Total submissions: 16
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000345676 | SCV000348854 | uncertain significance | Hutchinson-Gilford syndrome | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000284978 | SCV000348855 | uncertain significance | Dilated Cardiomyopathy, Dominant | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000342371 | SCV000348856 | uncertain significance | Mandibuloacral dysplasia | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000380612 | SCV000348857 | uncertain significance | Familial partial lipodystrophy | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000288324 | SCV000348858 | uncertain significance | Charcot-Marie-Tooth disease type 2 | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000345676 | SCV000348859 | uncertain significance | Hutchinson-Gilford syndrome | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000400023 | SCV000348860 | uncertain significance | Congenital muscular dystrophy due to LMNA mutation | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000310763 | SCV000348861 | uncertain significance | Lipoatrophy with Diabetes, Hepatic Steatosis, Hypertrophic Cardiomyopathy, and Leukomelanodermic Papules | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000348346 | SCV000348862 | uncertain significance | Limb-girdle muscular dystrophy, recessive | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000392349 | SCV000348863 | uncertain significance | Emery-Dreifuss muscular dystrophy | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000313247 | SCV000348864 | uncertain significance | Lethal tight skin contracture syndrome | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000345676 | SCV000348865 | uncertain significance | Hutchinson-Gilford syndrome | 2016-06-14 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV001262711 | SCV001440681 | uncertain significance | Dilated cardiomyopathy 1A | 2019-01-01 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV001814979 | SCV002061992 | uncertain significance | not specified | 2018-01-26 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000288324 | SCV003509116 | uncertain significance | Charcot-Marie-Tooth disease type 2 | 2023-08-10 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LMNA protein function. ClinVar contains an entry for this variant (Variation ID: 292838). This variant has not been reported in the literature in individuals affected with LMNA-related conditions. This variant is present in population databases (rs775159300, gnomAD 0.02%). This sequence change replaces arginine, which is basic and polar, with serine, which is neutral and polar, at codon 329 of the LMNA protein (p.Arg329Ser). |
Revvity Omics, |
RCV003488506 | SCV004236252 | uncertain significance | not provided | 2023-10-31 | criteria provided, single submitter | clinical testing |